Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Use of Pharmacogenetic Drugs by the Dutch Population

2 Jul 2019

Abstract excerpt

INTRODUCTION: The Dutch Pharmacogenetics Working Group (DPWG) indicated a list of actionable genotypes that affect patients' response to more 50 drugs; these drugs which show variable effects based on patients' genetic traits were named as pharmacogenetics (PGX) drugs. Preemptive genetic testing before using these drugs may protect certain patients from serious adverse reactions and could help in avoiding...

Topics

Join the communities discussing this publication.

Blood disorders and treatments
Pharmaceutical studies and practices
Pharmacogenetics and Drug Metabolism

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 31312209
DOI: 10.3389/fgene.2019.00567

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of Pharmacogenetic Drugs by the Dutch PopulationPMID 31312209Read ↗

Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The NetherlandsSemantic proximity Read ↗

Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx GuidelinesSemantic proximity Read ↗

A Narrative Review on Pharmacogenomics in Psychiatry: Scientific Definitions, Principles, and Practical Resources.Semantic proximity Read ↗

Genetic Risk Factors for Adverse Drug ReactionsSemantic proximity Read ↗

Estimating the prevalence of potential and actionable drug-gene interactions in Irish primary care: a cross-sectional studySemantic proximity Read ↗

Prevalence of actionable pharmacogenetic variants and high‐risk drug prescriptions: A Swiss hospital‐based cohort studySemantic proximity Read ↗

Pharmacogenetics: An Important Part of Drug Development with A Focus on Its ApplicationSemantic proximity Read ↗

Pharmacogenetic Testing: Time for Clinical Practice GuidelinesSemantic proximity Read ↗

Prevalence and correlates of pharmacotherapy metabolized by CYP2C19, CYP2C9, CYP2D6, and UGT1A1 in the population sample.Semantic proximity Read ↗

Pharmacotherapy Associated with CYP2C19, CYP2C9, CYP2D6, and UGT1A1 Genes in Population Sample: Observational Cross Sectional Analytical StudySemantic proximity Read ↗

Pharmacogenomics guidelines: Current status and future developmentSemantic proximity Read ↗

A retrospective analysis of preemptive pharmacogenomic testing in 22,918 individuals from China.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.